A phase I/II study using cabozantinib and lanreotide as treatments for advanced GEP-NETs for which molecular targeted therapy or chemotherapy have failed (SCALET): TCOG T2221 study.
BACKGROUND Somatostatin analogs (SSAs) and targeted therapies have shown efficacy for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in the past decades. To explore the therapeutic efficacy of SSA and targeted therapy combination, we conducted a phase I/II study to evaluate the toxicity and efficacy o...